AML's KRAS-mutant subtype has a two-doorway metabolic weakness, and a 2026 study names both doors

One emerging read of acute myeloid leukemia puts the lethal lesion on a two-doorway problem at the mitochondrion: block one transporter and the cell routes around it. The operational lesson from recent metabolic-vulnerability work is that both doors must be closed at once.

That is the synthetic-lethality frame the Cell Metabolism 2026 dual-targeting study makes concrete for KRAS-mutant AML, the aggressive subtype that shrugs off standard chemotherapy. SLC25A51 is the protein that imports NAD+ into mitochondria, and succinate dehydrogenase (SDH) is one of the main consumers of that NAD+. Block import and the cell starves; block the consumer and the import pathway compensates. Block both and the mitochondrial NAD+ pool collapses, and KRAS-driven leukemic cells die while normal progenitors survive.

The reusable category is metabolic synthetic lethality through coupled transporters, a frame any cancer with a defined mitochondrial fuel dependency can be re-tested against. For AML, the next translational steps are plain: build a selective SLC25A51 inhibitor, sequence it with SDH or complex I inhibitors, and test it in the older patients whose prognosis has barely moved in a decade. The biology is publishable. The drug is not yet here.